

Doravirine Formulation

Version	Revision Date:	SDS Number:	Date of last issue: 06.07.2024
5.1	28.09.2024	9371601-00009	Date of first issue: 27.08.2021

SECTION 1: Identification of the substance/mixture and of the company/undertaking

1.1	Product identifier Trade name	:	Doravirine Formulation
1.2	Relevant identified uses of th Use of the Sub- stance/Mixture		substance or mixture and uses advised against Pharmaceutical
	Recommended restrictions on use	:	Not applicable
1.3	Details of the supplier of the	saf	ety data sheet
	Company	:	MSD 120 Moorgate EC2M 6UR London, United Kingdom
	Telephone	:	+44 (0) 2081548000
	E-mail address of person responsible for the SDS	:	EHSDATASTEWARD@msd.com

1.4 Emergency telephone number

1-908-423-6000

SECTION 2: Hazards identification

2.1 Classification of the substance or mixture

Classification (REGULATION (EC) No 1272/2008) as amended by GB-CLP Regulation, UK SI 2019/720, and UK SI 2020/1567)

Not a hazardous substance or mixture.

2.2 Label elements

Labelling (REGULATION (EC) No 1272/2008) as amended by GB-CLP Regulation, UK SI 2019/720, and UK SI 2020/1567)

No hazard pictogram, no signal word, no hazard statement(s), no precautionary statement(s) required.

EUH210 Safety data sheet available on request.



Doravirine Formulation

Version	Revision Date:	SDS Number:	Date of last issue: 06.07.2024
5.1	28.09.2024	9371601-00009	Date of first issue: 27.08.2021

2.3 Other hazards

This substance/mixture contains no components considered to be either persistent, bioaccumulative and toxic (PBT), or very persistent and very bioaccumulative (vPvB) at levels of 0.1% or higher.

Dust contact with the eyes can lead to mechanical irritation.

Contact with dust can cause mechanical irritation or drying of the skin.

May form explosive dust-air mixture during processing, handling or other means.

SECTION 3: Composition/information on ingredients

3.2 Mixtures

Components

Chemical name	CAS-No. EC-No. Index-No. Registration number	Classification	Concentration (% w/w)
Doravirine	1338225-97-0		>= 10 - < 20
Substances with a workplace exposure	e limit :	•	
Cellulose	9004-34-6 232-674-9		>= 20 - < 30
Silicon, amorphous	112945-52-5		>= 1 - < 10

For explanation of abbreviations see section 16.

SECTION 4: First aid measures

4.1 Description of first aid measures

General advice	:	In the case of accident or if you feel unwell, seek medical ad- vice immediately. When symptoms persist or in all cases of doubt seek medical advice.
Protection of first-aiders	:	No special precautions are necessary for first aid responders.
If inhaled	:	If inhaled, remove to fresh air. Get medical attention if symptoms occur.
In case of skin contact	:	Wash with water and soap. Get medical attention if symptoms occur.
In case of eye contact	:	If in eyes, rinse well with water. Get medical attention if irritation develops and persists.
If swallowed	:	If swallowed, DO NOT induce vomiting. Get medical attention if symptoms occur. Rinse mouth thoroughly with water.



Doravirine Formulation

Vers 5.1	ion	Revision Date: 28.09.2024		9S Number: 71601-00009	Date of last issue: 06.07.2024 Date of first issue: 27.08.2021		
4.2 N		portant symptoms a	nd e		•		
	Risks		:	the skin.	t can cause mechanical irritation or drying of		
				Dust contact with	the eyes can lead to mechanical irritation.		
4.3 Indication of any immediate medical attention and special treatment needed							
	Treatm	ient	:	I reat symptomat	ically and supportively.		
SEC	TION	5: Firefighting meas	sure	es			
5.1 E	Extingu	ishing media					
	Suitabl	e extinguishing media	:	Water spray Alcohol-resistant	foam		
				Carbon dioxide (
				Dry chemical			
	Unsuita media	able extinguishing	:	None known.			
5.2 \$	Special	hazards arising from	the	substance or m	ixture		
	Specifi fighting	c hazards during fire- I	:	concentrations, a potential dust ex	dust; fine dust dispersed in air in sufficient and in the presence of an ignition source is a plosion hazard. bustion products may be a hazard to health.		
	Hazard	lous combustion prod-	:	Carbon oxides			
	ucts			Nitrogen oxides (Halogenated con			
				Metal oxides	ipounds		
5.3 A	Advice	for firefighters					
	Specia for firef	l protective equipment ighters	:		ned breathing apparatus for firefighting if nec- onal protective equipment.		
	Specifi ods	c extinguishing meth-	:	cumstances and Use water spray	g measures that are appropriate to local cir- the surrounding environment. to cool unopened containers. aged containers from fire area if it is safe to do		

6.1 Personal precautions, protective equipment and emergency procedures

Personal precautions	:	Follow safe handling advice (see section 7) and personal pro-	
		tective equipment recommendations (see section 8).	

According to REACH Regulation (EC) No 1907/2006, as amended by UK REACH Regulations SI 2019/758



Doravirine Formulation

Version 5.1	Revision Date: 28.09.2024	SDS Number: 9371601-00009	Date of last issue: 06.07.2024 Date of first issue: 27.08.2021	
6.2 Enviro	nmental precautions			
Environmental precautions		 Avoid release to the environment. Prevent further leakage or spillage if safe to do so. Retain and dispose of contaminated wash water. If spillage enters rivers or watercourses, inform the Environment Agency (emergency telephone number 0800 807060). 		
6.3 Metho	ds and material for co	ontainment and clea	aning up	
Methods for cleaning up		tainer for dispersa Avoid dispersa with compress Dust deposits es, as these m leased into the Local or nation posal of this m employed in th mine which re Sections 13 an	al of dust in the air (i.e., clearing dust surfaces	

6.4 Reference to other sections

See sections: 7, 8, 11, 12 and 13.

SECTION 7: Handling and storage

7.1 Precautions for safe handling

Technical measures	Static electricity may accumulate and ignite suspended dust causing an explosion. Provide adequate precautions, such as electrical grounding and bonding, or inert atmospheres.	
Local/Total ventilation Advice on safe handling	Use only with adequate ventilation. Do not breathe dust. Handle in accordance with good industrial hygiene and safet practice, based on the results of the workplace exposure as- sessment	
	Minimize dust generation and accumulation. Keep container closed when not in use. Keep away from heat and sources of ignition. Take precautionary measures against static discharges. Take care to prevent spills, waste and minimize release to the environment.	ıe
Hygiene measures	If exposure to chemical is likely during typical use, provide explicitly flushing systems and safety showers close to the working place. When using do not eat, drink or smoke. Wash contain nated clothing before re-use. The effective operation of a facility should include review of engineering controls, proper personal protective equipment, appropriate degowning and decontamination procedures, industrial hygiene monitoring, medical surveillance and the	



Doravirine Formulation

Versior 5.1	n Revision Date: 28.09.2024		DS Number: 71601-00009	Date of last issue: 06.07.2024 Date of first issue: 27.08.2021
			use of administra	tive controls.
7.2 Co	nditions for safe storage,	inc	luding any incom	patibilities
Requirements for storage areas and containers		:	Keep in properly labelled containers. Store in accordance with the particular national regulations.	
Advice on common storage		:	Do not store with the following product types: Strong oxidizing agents	
7.3 Sp	ecific end use(s)			
•	Specific use(s) : No data available		9	
			No data available)

SECTION 8: Exposure controls/personal protection

8.1 Control parameters

Occupational Exposure Limits

dust of any kind

10 mg/m3 Value type (Form of exposure): TWA (Inhalable) Basis: GB EH40

4 mg/m3 Value type (Form of exposure): TWA (Respirable fraction) Basis: GB EH40

Components	CAS-No.	Value type (Form of exposure)	Control parameters	Basis
Cellulose	9004-34-6	TWA (inhalable dust)	10 mg/m3	GB EH40
		TWA (Respirable dust)	4 mg/m3	GB EH40
		STEL (inhalable dust)	20 mg/m3	GB EH40
Doravirine	1338225- 97-0	TWA	500 ug/m3 (OEB2)	Internal
Silicon, amorphous	112945-52- 5	TWA (inhalable dust)	6 mg/m3 (Silica)	GB EH40
		TWA (Respirable dust)	2.4 mg/m3 (Silica)	GB EH40

8.2 Exposure controls

Engineering measures

Use feasible engineering controls to minimize exposure to compound. All engineering controls should be implemented by facility design and operated in accordance with GMP principles to protect products, workers, and the environment.

Personal protective equipment

According to REACH Regulation (EC) No 1907/2006, as amended by UK REACH Regulations SI 2019/758



Doravirine Formulation

Version 5.1	Revision Date: 28.09.2024	SDS Number: 9371601-00009	Date of last issue: 06.07.2024 Date of first issue: 27.08.2021
Eye/face protection		 Wear safety glasses with side shields or goggles. If the work environment or activity involves dusty conditions, mists or aerosols, wear the appropriate goggles. Wear a faceshield or other full face protection if there is a potential for direct contact to the face with dusts, mists, or aerosols. 	
Hand protection Material		: Chemical-res	istant gloves
Skin and body protection Respiratory protection		: If adequate lo sure assessm ommended g	or laboratory coat. cal exhaust ventilation is not available or expo- nent demonstrates exposures outside the rec- uidelines, use respiratory protection. nould conform to BS EN 143
Fil	ter type	: Particulates ty	

SECTION 9: Physical and chemical properties

9.1 Information on basic physical and chemical properties

Information on basic physical and chemical properties						
Appearance Colour	:	powder off-white				
Odour	÷	No data available				
Odour Threshold	:	No data available				
рН	:	No data available				
Melting point/freezing point	:	No data available				
Initial boiling point and boiling range	:	No data available				
Flash point	:	Not applicable				
Evaporation rate	:	Not applicable				
Flammability (solid, gas)	:	May form explosive dust-air mixture during processing, han- dling or other means.				
Upper explosion limit / Upper flammability limit	:	No data available				
Lower explosion limit / Lower flammability limit	:	No data available				
Vapour pressure	:	Not applicable				
Relative vapour density	:	Not applicable				
Relative density	:	No data available				
Density	:	No data available				
Solubility(ies)						

According to REACH Regulation (EC) No 1907/2006, as amended by UK REACH Regulations SI 2019/758



Doravirine Formulation

Version 5.1	Revision Date: 28.09.2024		Date of last issue: 06.07.2024 Date of first issue: 27.08.2021
Water solubility Partition coefficient: n- octanol/water Auto-ignition temperature Decomposition temperature		 No data available Not applicable No data available No data available 	
	sity scosity, kinematic sive properties	Not applicable	
Oxidiz	zing properties	The substance or i	mixture is not classified as oxidizing.
Flam	information nability (liquids) sular weight le size	No data availableNo data availableNo data available	

SECTION 10: Stability and reactivity

10.1 Reactivity

Not classified as a reactivity hazard.

10.2 Chemical stability

Stable under normal conditions.

10.3 Possibility of hazardous reactions

Hazardous reactions	:	May form explosive dust-air mixture during processing, han- dling or other means. Can react with strong oxidizing agents.
10.4 Conditions to avoid		
Conditions to avoid	:	Heat, flames and sparks. Avoid dust formation.
10.5 Incompatible materials Materials to avoid	:	Oxidizing agents
10.6 Hozardous decomposition r		luoto

10.6 Hazardous decomposition products

No hazardous decomposition products are known.

SECTION 11: Toxicological information

11.1 Information on toxicological effects

Information on likely routes of : Inhalation

According to REACH Regulation (EC) No 1907/2006, as amended by UK REACH Regulations SI 2019/758



Doravirine Formulation

rsion	Revision Date: 28.09.2024	SDS Number: 9371601-000	
expos	sure	Skin conta Ingestion Eye conta	
Acute	e toxicity		
Not cl	assified based on ava	ailable information	
<u>Comp</u>	oonents:		
Dora	virine:		
Acute	oral toxicity): > 750 mg/kg No mortality observed at this dose.
			thod: Phototoxicity No evidence of phototoxicity was observed
			g): > 1,000 mg/kg No mortality observed at this dose.
			use): > 450 mg/kg No mortality observed at this dose.
Cellu	lose:		
Acute	oral toxicity	: LD50 (Rat): > 5,000 mg/kg
Acute	inhalation toxicity	Exposure): > 5.8 mg/l time: 4 h sphere: dust/mist
Acute	e dermal toxicity	: LD50 (Ral	obit): > 2,000 mg/kg
Silico	on, amorphous:		
	oral toxicity	Method: C): > 5,000 mg/kg ECD Test Guideline 401 Based on data from similar materials
Acute	inhalation toxicity	Exposure Test atmo Assessme tion toxicit	sphere: dust/mist nt: The substance or mixture has no acute inh
Acute	e dermal toxicity		obit): > 5,000 mg/kg Based on data from similar materials

Not classified based on available information.

Components:

Doravirine:

According to REACH Regulation (EC) No 1907/2006, as amended by UK REACH Regulations SI 2019/758



ersion 1	Revision Date: 28.09.2024	SDS Number:Date of last issue: 06.07.20249371601-00009Date of first issue: 27.08.2021	
Rema	arks	: No data available	
Silico Speci Metho Resul Rema	od It	 Rabbit OECD Test Guideline 404 No skin irritation Based on data from similar materials 	
Not cl	us eye damage/eye lassified based on av		
<u>Comp</u>	oonents:		
Dora v Rema	virine: arks	: No data available	
Silico Speci Metho Resul Rema	od It	 Rabbit OECD Test Guideline 405 No eye irritation Based on data from similar materials 	
Resp	iratory or skin sens	tisation	
-	sensitisation lassified based on av	ailable information.	
-	iratory sensitisation assified based on av		
<u>Com</u>	oonents:		
Dora v Rema	virine: arks	: No data available	
	a cell mutagenicity lassified based on av	ailable information.	
<u>Com</u>	oonents:		
Dora	virine:		
Geno	toxicity in vitro	: Test Type: Bacterial reverse mutation assay (AME Result: negative	ES)
		Test Type: Chromosomal aberration Test system: Chinese hamster ovary cells Result: negative	
Geno	toxicity in vivo	: Test Type: Micronucleus test Species: Rat Cell type: Bone marrow	
		9/18	

According to REACH Regulation (EC) No 1907/2006, as amended by UK REACH Regulations SI 2019/758



	28.09.2024	9371601-00009 Date of first issue: 27.08.2021	
		Application Route: Oral Result: negative	
Cellulo	ose:		
	oxicity in vitro	: Test Type: Bacterial reverse mutation assay (AMES) Result: negative	
		Test Type: In vitro mammalian cell gene mutation test Result: negative	
Genoto	oxicity in vivo	: Test Type: Mammalian erythrocyte micronucleus test (in cytogenetic assay) Species: Mouse Application Route: Ingestion Result: negative	vivo
Silicor	n, amorphous:		
	oxicity in vitro	 Test Type: Bacterial reverse mutation assay (AMES) Method: OECD Test Guideline 471 Result: negative Remarks: Based on data from similar materials 	
Genoto	oxicity in vivo	 Test Type: Mutagenicity (in vivo mammalian bone-marrov cytogenetic test, chromosomal analysis) Species: Rat Application Route: Ingestion Result: negative Remarks: Based on data from similar materials 	N
Carcir	ogenicity		
	assified based on av	ilable information.	
<u>Comp</u>	onents:		
Doravi	irine:		
Specie	S	: Mouse	
	ation Route	: Oral	
Exposi Result	ure time	: 6 Months : negative	
Remar		: No significant adverse effects were reported	
Cellulo	ose.		
Specie		: Rat	
	ation Route	: Ingestion	
	ure time	: 72 weeks	
Result		: negative	
Silicor	n, amorphous:		
Specie		: Rat	
	ation Route	: Ingestion	

According to REACH Regulation (EC) No 1907/2006, as amended by UK REACH Regulations SI 2019/758



Doravirine Formulation

Vers 5.1	sion	Revision Date: 28.09.2024		S Number: 71601-00009	Date of last issue: 06.07.2024 Date of first issue: 27.08.2021			
	Exposure time Result Remarks		: :	 103 weeks negative Based on data from similar materials 				
	Reproductive toxicity Not classified based on availab			information.				
	Compo	onents:						
	Doravi	rine:						
	Effects	on fertility	:	Test Type: Fertilit Species: Rat, mal Fertility: NOAEL: Result: No effects	e and female 450 mg/kg body weight			
	Effects ment	on foetal develop-	:	Species: Rat Application Route Developmental To Result: No advers Test Type: Embry Species: Rabbit Application Route	oxicity: NOAEL: 450 mg/kg body weight se effects ro-foetal development : Oral			
				Developmental To Result: No advers	oxicity: NOAEL: 300 mg/kg body weight se effects			
	Cellulo							
	Effects	on fertility	:	Test Type: One-g Species: Rat Application Route Result: negative	eneration reproduction toxicity study : Ingestion			
	Effects ment	on foetal develop-	:	Test Type: Fertilit Species: Rat Application Route Result: negative	y/early embryonic development : Ingestion			
		a, amorphous: on foetal develop-	:	Species: Rat Application Route Result: negative	ro-foetal development : Ingestion on data from similar materials			

STOT - single exposure

Not classified based on available information.

STOT - repeated exposure

Not classified based on available information.

According to REACH Regulation (EC) No 1907/2006, as amended by UK REACH Regulations SI 2019/758



rsion	Revision Date: 28.09.2024	SDS Number: 9371601-00009	Date of last issue: 06.07.2024 Date of first issue: 27.08.2021
Repe	ated dose toxicity		
Com	ponents:		
Dora	virine:		
	EL cation Route sure time	: Rat : 450 mg/kg : Oral : 6 Months : No significant a	dverse effects were reported
	EL cation Route sure time	: Mouse : > 450 mg/kg : Oral : 3 Months : No significant a	dverse effects were reported
	EL cation Route sure time	: Dog : > 1,000 mg/kg : Oral : 9 Months : No significant a	dverse effects were reported
Cellu	lose:		
Speci NOAE Applic	ies	: Rat : >= 9,000 mg/kg : Ingestion : 90 Days	I
Silico	on, amorphous:		
Speci NOAE Applic	ies EL cation Route sure time	: Rat : 1.3 mg/l : inhalation (dust : 13 Weeks : Based on data	/mist/fume) from similar materials
-	ration toxicity lassified based on av	ailable information	
	rience with human e		
•	ponents:	-	
-	virine:		
Inges	-		fusion, Headache, Dizziness, Nausea, Rasł ns, flushing, Neurological disorders, mental

According to REACH Regulation (EC) No 1907/2006, as amended by UK REACH Regulations SI 2019/758



Doravirine Formulation

Version	Revision Date:	SDS Number:	Date of last issue: 06.07.2024
5.1	28.09.2024	9371601-00009	Date of first issue: 27.08.2021

SECTION 12: Ecological information

12.1 Toxicity

Components:		
Doravirine: Toxicity to daphnia and other		EC50 (Daphnia magna (Water flea)): > 39 mg/l
aquatic invertebrates	•	Exposure time: 48 h Method: OECD Test Guideline 202 Remarks: No toxicity at the limit of solubility
		EC50 (Americamysis): 9.1 mg/l Exposure time: 96 h
Toxicity to algae/aquatic plants	:	EC50 (Pseudokirchneriella subcapitata (green algae)): > 5.8 mg/l Exposure time: 72 h Method: OECD Test Guideline 201 Remarks: No toxicity at the limit of solubility
		NOEC (Pseudokirchneriella subcapitata (green algae)): 5.8 mg/l Exposure time: 72 h Method: OECD Test Guideline 201 Remarks: No toxicity at the limit of solubility
Toxicity to microorganisms	:	EC50 : > 1,000 mg/l Exposure time: 3 h Test Type: Respiration inhibition Method: OECD Test Guideline 209
		NOEC : 1,000 mg/l Exposure time: 3 h Test Type: Respiration inhibition Method: OECD Test Guideline 209
Toxicity to fish (Chronic tox- icity)	:	NOEC: 1 mg/l Exposure time: 32 d Species: Pimephales promelas (fathead minnow) Method: OECD Test Guideline 210 Remarks: No toxicity at the limit of solubility
Toxicity to daphnia and other aquatic invertebrates (Chron- ic toxicity)	:	NOEC: 6.7 mg/l Exposure time: 21 d Species: Daphnia magna (Water flea) Method: OECD Test Guideline 211 Remarks: No toxicity at the limit of solubility
Cellulose:		
Toxicity to fish	:	LC50 (Oryzias latipes (Japanese medaka)): > 100 mg/l Exposure time: 48 h

According to REACH Regulation (EC) No 1907/2006, as amended by UK REACH Regulations SI 2019/758



Versic 5.1	on	Revision Date: 28.09.2024		9S Number: 71601-00009	Date of last issue: 06.07.2024 Date of first issue: 27.08.2021
				Remarks: Based o	n data from similar materials
		, amorphous: to fish	:	Exposure time: 96 Method: OECD Te	
		to daphnia and other invertebrates	:	Exposure time: 24 Method: OECD Te	
	Toxicity to algae/aquatic plants		:	EC50 (Desmodesmus subspicatus (green algae)): > 10,00 mg/l Exposure time: 72 h Method: OECD Test Guideline 201 Remarks: Based on data from similar materials	
				mg/l Exposure time: 72 Method: OECD Te	
12.2 F	Persist	ence and degradabil	ity		
<u>C</u>	Compo	nents:			
_	Doravir Biodegr	ine: adability	:	Result: Not readily Biodegradation: 2 Exposure time: 28	%
-	Cellulo : Biodegr	se: adability	:	Result: Readily bio	odegradable.
12.3 E	Bioacc	umulative potential			
<u>C</u>	Compo	nents:			
P	Doravir Partitior octanol/	n coefficient: n-	:	log Pow: 2.08	
12.4 N	Nobilit	y in soil			
<u>c</u>	Compo	nents:			
D		ine: tion among environ- compartments	:	log Koc: 2.86	

According to REACH Regulation (EC) No 1907/2006, as amended by UK REACH Regulations SI 2019/758



Doravirine Formulation

Version	Revision Date:	SDS Number:	Date of last issue: 06.07.2024
5.1	28.09.2024	9371601-00009	Date of first issue: 27.08.2021

12.5 Results of PBT and vPvB assessment

Ρ	ro	d	uc	:t:

Assessment : This substance/mixture contains no components considered to be either persistent, bioaccumulative and toxic (PBT), or very persistent and very bioaccumulative (vPvB) at levels of 0.1% or higher.

12.6 Other adverse effects

Product:

Flouuci.		
Endocrine disrupting poten-	:	This substance/mixture does not contain components consid-
tial		ered to have endocrine disrupting properties for environment
		according to UK REACH Article 57(f).

SECTION 13: Disposal considerations

13.1 Waste treatment methods

Product	 Dispose of in accordance with local regulations. According to the European Waste Catalogue, Waste Codes are not product specific, but application specific. Waste codes should be assigned by the user, preferably in discussion with the waste disposal authorities. Do not dispose of waste into sewer.
Contaminated packaging	 Empty containers should be taken to an approved waste han- dling site for recycling or disposal. If not otherwise specified: Dispose of as unused product.

SECTION 14: Transport information

14.1 UN number

ADN	:	Not regulated as a dangerous good
ADR	:	Not regulated as a dangerous good
RID	:	Not regulated as a dangerous good
IMDG	:	Not regulated as a dangerous good
ΙΑΤΑ	:	Not regulated as a dangerous good
14.2 UN proper shipping name		
ADN	:	Not regulated as a dangerous good
ADR	:	Not regulated as a dangerous good
ADR RID	:	Not regulated as a dangerous good Not regulated as a dangerous good
	::	5 5 5
RID	-	Not regulated as a dangerous good

14.3 Transport hazard class(es)

According to REACH Regulation (EC) No 1907/2006, as amended by UK REACH Regulations SI 2019/758



Doravirine Formulation

Version 5.1	Revision Date: 28.09.2024	SDS Number:Date of last issue: 06.07.20249371601-00009Date of first issue: 27.08.2021	
AD	Ν	: Not regulated as a dangerous good	
AD	R	: Not regulated as a dangerous good	
RIE)	: Not regulated as a dangerous good	
IME	DG	: Not regulated as a dangerous good	
ΙΑΙ	A	: Not regulated as a dangerous good	
14.4 Pa	cking group		
AD	N	: Not regulated as a dangerous good	
AD	R	: Not regulated as a dangerous good	
RIE)	: Not regulated as a dangerous good	
IME	DG	: Not regulated as a dangerous good	
ΙΑΙ	A (Cargo)	: Not regulated as a dangerous good	
ΙΑΙ	A (Passenger)	: Not regulated as a dangerous good	
	vironmental hazards regulated as a dangerou	is good	

14.6 Special precautions for user

Not applicable

14.7 Transport in bulk according to Annex II of Marpol and the IBC Code

Remarks

: Not applicable for product as supplied.

SECTION 15: Regulatory information

15.1 Safety, health and environmental regulations/legislation specific for the substance or mixture

Relevant EU provisions transposed through retained EU law

UK REACH List of restrictions (Annex 17)	:	Not applicable
UK REACH Candidate list of substances of very high concern (SVHC) for Authorisation	:	Not applicable
The Persistent Organic Pollutants Regulations (retained Regulation (EU) 2019/1021 as amended for Great Brit-	:	Not applicable
ain) Regulation (EC) on substances that deplete the ozone laver	:	Not applicable
UK REACH List of substances subject to authorisation (Annex XIV)	:	Not applicable
GB Export and import of hazardous chemicals - Prior Informed Consent (PIC) Regulation	:	Not applicable
Control of Major Accident Hazards Regulations 2015 (CC Not applicable	MA	\H)

The components of this product are reported in the following inventories: AICS

: not determined



Doravirine Formulation

Version 5.1	Revision Date: 28.09.2024	SDS Number: 9371601-00009	Date of last issue: 06.07.2024 Date of first issue: 27.08.2021
DSL		: not determined	
IECS	C	: not determined	
15.2 Cherr	nical safety assessme	ent	

A Chemical Safety Assessment has not been carried out.

SECTION 16: Other information

Other information	:	Items where changes have been made to the previous version are highlighted in the body of this document by two vertical lines.

Full text of other abbreviations

GB EH40	:	UK. EH40 WEL - Workplace Exposure Limits
GB EH40 / TWA	:	Long-term exposure limit (8-hour TWA reference period)
GB EH40 / STEL	:	Short-term exposure limit (15-minute reference period)

ADN - European Agreement concerning the International Carriage of Dangerous Goods by Inland Waterways; ADR - Agreement concerning the International Carriage of Dangerous Goods by Road; AIIC - Australian Inventory of Industrial Chemicals; ASTM - American Society for the Testing of Materials; bw - Body weight; CLP - Classification Labelling Packaging Regulation; Regulation (EC) No 1272/2008; CMR - Carcinogen, Mutagen or Reproductive Toxicant; DIN - Standard of the German Institute for Standardisation; DSL - Domestic Substances List (Canada); ECHA -European Chemicals Agency; EC-Number - European Community number; ECx - Concentration associated with x% response; ELx - Loading rate associated with x% response; EmS - Emergency Schedule; ENCS - Existing and New Chemical Substances (Japan); ErCx - Concentration associated with x% growth rate response; GHS - Globally Harmonized System; GLP - Good Laboratory Practice; IARC - International Agency for Research on Cancer; IATA - International Air Transport Association; IBC - International Code for the Construction and Equipment of Ships carrying Dangerous Chemicals in Bulk; IC50 - Half maximal inhibitory concentration; ICAO - International Civil Aviation Organization; IECSC - Inventory of Existing Chemical Substances in China; IMDG - International Maritime Dangerous Goods; IMO - International Maritime Organization; ISHL - Industrial Safety and Health Law (Japan); ISO - International Organisation for Standardization; KECI - Korea Existing Chemicals Inventory; LC50 - Lethal Concentration to 50 % of a test population; LD50 - Lethal Dose to 50% of a test population (Median Lethal Dose); MARPOL - International Convention for the Prevention of Pollution from Ships; n.o.s. - Not Otherwise Specified; NO(A)EC - No Observed (Adverse) Effect Concentration; NO(A)EL - No Observed (Adverse) Effect Level; NOELR - No Observable Effect Loading Rate; NZIoC - New Zealand Inventory of Chemicals; OECD - Organization for Economic Co-operation and Development; OPPTS - Office of Chemical Safety and Pollution Prevention; PBT - Persistent, Bioaccumulative and Toxic substance; PICCS - Philippines Inventory of Chemicals and Chemical Substances; (Q)SAR - (Quantitative) Structure Activity Relationship; REACH - Regulation (EC) No 1907/2006 of the European Parliament and of the Council concerning the Registration, Evaluation, Authorisation and Restriction of Chemicals; RID - Regulations concerning the International Carriage of Dangerous Goods by Rail; SADT - Self-Accelerating Decomposition Temperature; SDS - Safety Data Sheet; SVHC - Substance of very high concern; TCSI - Taiwan Chemical Substance Inventory; TECI -Thailand Existing Chemicals Inventory; TSCA - Toxic Substances Control Act (United States); UN - United Nations; UNRTDG - United Nations Recommendations on the Transport of Dangerous Goods; vPvB - Very Persistent and Very Bioaccumulative



Doravirine Formulation

Version	Revision Date:	SDS Number:	Date of last issue: 06.07.2024
5.1	28.09.2024	9371601-00009	Date of first issue: 27.08.2021

Further information

Sources of key data used to compile the Safety Data Sheet : Internal technical data, data from raw material SDSs, OECD eChem Portal search results and European Chemicals Agency, http://echa.europa.eu/

The information provided in this Safety Data Sheet is correct to the best of our knowledge, information and belief at the date of its publication. The information is designed only as a guidance for safe handling, use, processing, storage, transportation, disposal and release and shall not be considered a warranty or quality specification of any type. The information provided relates only to the specific material identified at the top of this SDS and may not be valid when the SDS material is used in combination with any other materials or in any process, unless specified in the text. Material users should review the information and recommendations in the specific context of their intended manner of handling, use, processing and storage, including an assessment of the appropriateness of the SDS material in the user's end product, if applicable.

GB / EN